Fate Therapeutics gives Q3 2026 update on lupus CAR T program and FT839 trial sitesNov 10Regulatory decisionAutolus Therapeutics plcFate TherapeuticsUpdated
Fate Therapeutics registers Phase 1/2 trial of FT839 across five autoimmune diseasesSep 2Trial updateFate TherapeuticsFT839
Fate Therapeutics doses first lupus nephritis patient in Phase 2 FT819 trial, clears FT839 INDAug 13Quarterly updateFate TherapeuticsFT819